XLRN - Bristol Myers Acceleron's Reblozyl shows encouraging action in adults with beta thalassemia

Bristol Myers Squibb (BMY) and Acceleron Pharma (XLRN) announce the first data from Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt) plus best supportive care in adult patients with non-transfusion dependent ((NTD)) beta thalassemia.Results demonstrated that 77.7% of patients treated with Reblozyl achieved the primary endpoint, a hemoglobin increase (?1.0 gram/deciliter) compared to 0% in the placebo arm. In a key secondary endpoint, 50 of 96 patients (52.1%) in the Reblozyl arm achieved mean Hb increase of ?1.5 g/dL compared to baseline vs 0 patients (0%) in the placebo arm (P<0.0001).89.6% of patients in the Reblozyl arm remained transfusion free at weeks 1-24 vs. 67.3% in placebo arm (P=0.0013).Reblozyl was generally well tolerated and improvements in patient-reported QoL outcomes were also observed to correlate with Hb increases.The data were presented at the EHA 2021 Virtual Congress.#EHA21

For further details see:

Bristol Myers, Acceleron's Reblozyl shows encouraging action in adults with beta thalassemia